English 
Hindi 
Eli Lilly debuted Mounjaro (tirzepatide), its popular weight loss and diabetes therapy in India. Mounjaro has been approved by the Central Drugs Standard Control Organization (CDSCO) and is the first and only medication approved that targets both GIP and GLP-1 receptors respectively in modulating or controlling blood glucose levels and weight.
Price Details:
Lilly has launched Mounjaro into India at much lower prices than in the US. It is sold as a single dose vial costing ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial. The cost ranges from ₹14,000 to ₹17,500 for monthly treatment which is approximately one fifth the US drug price of $1,000 – $1,200.
Read Also: The Spring Equinox Is Here! Everything You Need to Know
Side Effects:
While Mounjaro has demonstrated impressive weight loss advantages, the side effects including nausea, vomiting, diarrhea, loss of appetite and constipation should be noted. Long term risks are rare but could include stomach problems, kidney problems and pancreatitis.
Market Reaction:
The market for anti obesity medications in India has escalated as the market size grew from ₹137 crore in 2020 to ₹535 crore by 2024. With Novo Nordisk‘s semaglutide being the current leader in market share, there is expected to be more competition with the arrival of Mounjaro. Experts have high expectations for the launch and how it will reshape the diabetes and obesity market in India.
